Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel. Ysios participated.
09/06/2022 Press release MINERALYS THERAPEUTICS CLOSES $118 MILLION OVERSUBSCRIBED SERIES B FINANCING TO ADVANCE THE DEVELOPMENT OF NOVEL. YSIOS CAPITAL PARTICIPATED. Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel. Ysios participated. MLS-101 is a Highly Selective Aldosterone Synthase Inhibitor Designed to Address Abnormally Elevated Aldosterone, an Underlying Cause…